Table of Contents
<< Previous Issue | Nov 2017 (Vol: 2017, Issue: 11) | Next Issue >> |
- Section: Licensing
-
Incyte Inks US$900 M Deal with MacroGenics to Develop PD-1 Inhibitor
-
Sanofi Signs Deal with Principia to Strengthen its Position in Multiple Sclerosis
-
Bayer Bolsters Pipeline with Two US$1 Billion Dollar Deals
- Section: Mergers & Acquisitions
-
Novartis Bolsters Oncology Portfolio with US$3.9 B Purchase of AAA
- Section: Research & Development
-
BMS Looks to Galvanise Opdivo’s Prospects with Halozyme’s Technology
-
Sumitomo Dainippon Gains Asian Rights to Poxel’s Late-Stage Diabetes Drug